The year 2011 was marked by major achievements of its key
assets and by determining strategic orientations that enable
BioAlliance Pharma to enter 2012 with strong growth prospects
on its two product portfolios.
Orphan oncology product portfolio:
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1006 EUR | -4.19% |
|
-0.40% | -39.03% |
![Consensus](/images/consensus_flch.gif)
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.03% | 16.77M | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- ALVIO Stock
- News Valerio Therapeutics
- BIOALLIANCE PHARMA : 2011 achievements and 2012 prospects - BioAlliance Pharma confirms the dynamics of its core business (PDF - 360 Ko)